Advertisement

Topics

Merck’s Antiviral Drug Letermovir Meets Primary Endpoint in Late-Stage Trial

09:41 EDT 19 Oct 2016 | Speciality Pharma Journal

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus …

Original Article: Merck’s Antiviral Drug Letermovir Meets Primary Endpoint in Late-Stage Trial

NEXT ARTICLE

More From BioPortfolio on "Merck’s Antiviral Drug Letermovir Meets Primary Endpoint in Late-Stage Trial"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...